AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02117349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelfoam
Description: Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
Study NCT02117349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rescue treatment
Description: Thrombin-containing hemostats included in standard care at the site
Study NCT02117349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue treatment
Description: Thrombin-containing hemostats included in standard care at the site
Study NCT01762995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
Study NCT01762995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate 1200 mg
Description: Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
Study NCT01762995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Fumarate 324 mg
Description: One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
Study NCT00590577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 25 mg eq.
Description: Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
Study NCT00590577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 150 mg eq.
Description: Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
Study NCT00590577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.m. Days 1, 8, 36, 64
Study NCT00590577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg eq.
Description: Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
Study NCT02752464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
Study NCT02752464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: feedback report
Description: All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
Study NCT02752464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feedback report
Description: All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
Study NCT01805388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Regeneration Treatment Group
Description: Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
Study NCT01805388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control Non-Study Drug Group
Description: Endodontic RTC with no study drug
Study NCT03757754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 2.5 mg/m2
Description: HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study NCT03757754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 3 mg/m2
Description: HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study NCT03757754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 3.5 mg/m2
Description: HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study NCT03757754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 4 mg/m2
Description: HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study NCT03757754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 5 mg/m2
Description: HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study NCT03757754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 6 mg/m2
Description: HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study NCT00513396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
Study NCT00513396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
Study NCT00513396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
Study NCT04166760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: speWHE
Description: 25 gram of a specific whey fraction (confidential)
Study NCT04166760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WHE
Description: 25 gram protein of a regular whey compound
Study NCT00969072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 0.05mg
Description: GI198745 (drug) - benign prostatic hyperplasia
Study NCT00969072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 0.5mg
Description: GI198745 (drug) - benign prostatic hyperplasia
Study NCT00969072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 2.5mg
Description: GI198745 (drug) - benign prostatic hyperplasia
Study NCT01803867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rHIgM22
Description: Administered via IV infusion
Study NCT03481621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).
Study NCT03481621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: PT, pain medications, nerve block, etc
Study NCT04445376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercises
Description: Aerobic Training and Breathing Exercises.
Study NCT02851823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal curettes
Study NCT02851823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er-YAG+Nd-YAG lasers
Study NCT02530736 — intervention group
Intervention type: OTHER
Intervention: 4 metre gait speed
Description: Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
Study NCT02584920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Study NCT02584920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT03765827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamine E Acetate
Description: Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
Study NCT03765827 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No application of vitamin E acetate
Description: Vitamin E acetate ointment will not be applied in this group
Study NCT01454570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: powered exoskeleton
Study NCT00772707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)
Description: OPTI-FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
Study NCT00772707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses
Description: Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
Study NCT01275833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy-defibrillator
Description: Device programming that modifies AV timing
Study NCT03451149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency wire (Powerwire)
Description: Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
Study NCT02382679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Vitamin Mixture
Description: Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
Study NCT02382679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
Study NCT01014429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-1286937
Description: Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
Study NCT02046408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Tablet
Study NCT02041533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT02041533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study NCT03562728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRP and NMES(neuromuscular electric stimulation)
Description: nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
Study NCT03562728 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients in the control group are going to receive standard of care
Study NCT04789005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
Study NCT04789005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
Study NCT01475227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Solvazinc tablet, day 2 to day 15
Description: Zinc sulphate 125mg, day 2 to day 15
Study NCT01475227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Solvazinc tablet, day 15 to day 28
Description: Zinc sulphate 125mg, day 15 to day 28
Study NCT02005679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: application of the mini-mental state test
Study NCT02065479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Comparison of platelet reactivity between prasugrel and ticagrelor
Study NCT02065479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Comparison of platelet reactivity between prasugrel and ticagrelor
Study NCT04018833 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
Study NCT04018833 — intervention group
Intervention type: DRUG
Intervention: Aflibercept 40 MG/ML Intraocular Solution [EYLEA]
Study NCT00529854 — intervention group
Intervention type: OTHER
Intervention: SIC-IR Billing Module
Description: Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
Study NCT00803868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: up to 1mg po bid for 9 weeks
Study NCT00803868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching study drug up to 1mg po bid
Study NCT05398432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: After the pre-test data were applied to all patients, before starting the motivational interview seans, the patients were informed about the interview intervals, duration, and how many times they would be held. In the second week, motivational interview seans were started with the patients. seans with patients took place during the hemodialysis seans. A total of 6 seans were held, one seans per week. After the first seans of the self-care supported motivational interview, the Self-Care and Adaptation to Disease Training Guide prepared by the researcher in line with the literature was given to the experimental group. Self-care training was given in the first, second and third seans. Motivational interviews were conducted in the fourth, fifth and sixth seans. Motivational interviewing techniques were used for patients to realize their self-care activities. seans were held individually with the patients and each seans lasted approximately 15-20 minutes.
Study NCT01561820 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5-month aerobic exercise intervention
Description: The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5\[HRmax-HRrest\]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
Study NCT01561820 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 5-month aerobic exercise intervention
Description: The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5\[HRmax-HRrest\]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
Study NCT03491995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Description: Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
Study NCT02356198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal hydromorphone
Description: Intrathecal opioid administration
Study NCT04008953 — intervention group
Intervention type: DEVICE
Intervention: ultrasonography
Description: Intravascular volume assessment using ultrasonography, CVP and echocardiography
Study NCT01366352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNTX tablet (Formulation 1)
Study NCT01562327 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Participants received tocilizumab according to individualized physician-prescribed regimens.
Study NCT04083521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DE111®
Description: Subjects were administered a dose of Bacillus subtilis at levels of 1x10\^9 CFU once a day for 90-days.
Study NCT02312375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: 16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
Study NCT02312375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
Study NCT01366352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNTX tablet (Formulation 2)
Study NCT02042092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study NCT01238965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given orally
Study NCT01238965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02198183 — intervention group
Intervention type: DEVICE
Intervention: Casmed Fore-Sight Elite
Study NCT02198183 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive Cardiac Output Monitor (NICOM)
Study NCT03243981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sciton SkinTyte (800-1800 nm) with Broadband Light Technology
Description: This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
Study NCT01483378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Choosing to receive the vaccine
Study NCT02147964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone 1% Gel
Description: Testosterone 1% gel 5g daily for 4 months \[all subjects\]
Study NCT00281359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With heat
Description: heat pad followed by dynamic splinting
Study NCT00281359 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No heat
Description: No heat added to tissue prior to dynamic splinting
Study NCT01831570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GENETIC and radiographs
Description: GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
Study NCT01238965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01238965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT01238965 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT01238965 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies
Study NCT01238965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01238965 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT01238965 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies
Study NCT01238965 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study NCT01416428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oprozomib
Description: Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.